Cisplatin (CDDP) is commonly used to treat a multitude of tumors including sarcomas, ovarian and cervical cancers. Despite recent investigations allowed to improve chemotherapy effectiveness, the molecular mechanisms underlying the development of CDDP resistance remain a major goal in cancer research. Here, we show that mitochondrial morphology and autophagy are altered in different CDDP resistant cancer cell lines. In CDDP resistant osteosarcoma and ovarian carcinoma, mitochondria are fragmented and closely juxtaposed to the endoplasmic reticulum; rates of mitophagy are also increased. Specifically, levels of the mitophagy receptor BNIP3 are higher both in resistant cells and in ovarian cancer patient samples resistant to platinum-based treatments. Genetic BNIP3 silencing or pharmacological inhibition of autophagosome formation re-sensitizes these cells to CDDP. Our study identifies inhibition of BNIP3-driven mitophagy as a potential therapeutic strategy to counteract CDDP resistance in ovarian carcinoma and osteosarcoma.

Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Canzonieri, Vincenzo;
2022

Abstract

Cisplatin (CDDP) is commonly used to treat a multitude of tumors including sarcomas, ovarian and cervical cancers. Despite recent investigations allowed to improve chemotherapy effectiveness, the molecular mechanisms underlying the development of CDDP resistance remain a major goal in cancer research. Here, we show that mitochondrial morphology and autophagy are altered in different CDDP resistant cancer cell lines. In CDDP resistant osteosarcoma and ovarian carcinoma, mitochondria are fragmented and closely juxtaposed to the endoplasmic reticulum; rates of mitophagy are also increased. Specifically, levels of the mitophagy receptor BNIP3 are higher both in resistant cells and in ovarian cancer patient samples resistant to platinum-based treatments. Genetic BNIP3 silencing or pharmacological inhibition of autophagosome formation re-sensitizes these cells to CDDP. Our study identifies inhibition of BNIP3-driven mitophagy as a potential therapeutic strategy to counteract CDDP resistance in ovarian carcinoma and osteosarcoma.
apr-2022
Pubblicato
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033831/pdf/41419_2022_Article_4741.pdf
File in questo prodotto:
File Dimensione Formato  
Cisplatin+resistance+can+be+curtailed+by+blunting.pdf

accesso aperto

Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 9.37 MB
Formato Adobe PDF
9.37 MB Adobe PDF Visualizza/Apri
41419_2022_4741_MOESM1_ESM.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 82.14 kB
Formato Adobe PDF
82.14 kB Adobe PDF Visualizza/Apri
41419_2022_4741_MOESM2_ESM.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 277.62 kB
Formato Adobe PDF
277.62 kB Adobe PDF Visualizza/Apri
41419_2022_4741_MOESM3_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 41.43 MB
Formato TIFF
41.43 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM4_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 24.21 MB
Formato TIFF
24.21 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM5_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 37.47 MB
Formato TIFF
37.47 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM6_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 35.43 MB
Formato TIFF
35.43 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM7_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 42.25 MB
Formato TIFF
42.25 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM8_ESM.tif

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 29.15 MB
Formato TIFF
29.15 MB TIFF Visualizza/Apri
41419_2022_4741_MOESM9_ESM.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 925.87 kB
Formato Adobe PDF
925.87 kB Adobe PDF Visualizza/Apri
41419_2022_4741_MOESM10_ESM.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/3028346
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact